Table 5.

Probability of related outcomes to multiple sclerosis (MS) and interferon beta (INF β) therapy

	Natural History		Interferon beta-1a		Interferon beta-1a 44 Mcg/0.5 ml		Interferon beta-1b
			(Avonex)		(Rebif)		(Betaferon)
Probability of EDSS progression within RRMS
RRMS 1-3 to RRMS 3.5-6	0.4		0.219		0.193		0.2
RRMS 3.5-6 to RRMS 6≤	0.27		0.11		0.115		0.15
Probability of progression from RRMS to SPMS (the same EDSS)
RRMS 3.5-6 to SPMS 3.5-6	0.43		0.43		0.197		0.433
RRMS 6≤ to SPMS 6≤	0.31		0.31		0.31		0.31
Probability of EDSS progression within SPMS
SPMS 3.5-6 to SPMS 6≤	0.5		0.3		0.5		0.4
Relapse rate
RRMS	Cycle 1	2.54	Cycle 1	1.34	Cycle 1	1.73	Cycle 1	1.68
	Other cycles	2.04	Other cycles	1.31	Other cycles	1.18	Other cycles	1.01
SPMS	0.7		0.47		0.5		0.35
Withdrawal
RRMS 1-3	-		Cycles1 &2	0.04	Cycles1 &2	0.078	Cycles1 &2	0.086
			Other cycles	0.04	Other cycles	0.05	Other cycles	0.09
RRMS 3.5-6	-		Cycle 2	0.26	Cycle 2	0.42	Cycle 2	0.247
			Other cycles	0.04	Other cycles	0.05	Other cycles	0.09
SPMS 3.5-6	-		0.19		0.357		0.25

RRMS relapsing remitting multiple sclerosis, SPMS secondary progressive multiple sclerosis, EDSS expanded disability status scale, Mcg microgram, ml milliliter.